EGFR and glioblastoma: Subsequently, we found that IDH1/2 mutation, but not MGMT methylation status was correlated with CNVs of LANCL2 and EGFR. However, amplification of LANCL2/EGFR and their co-amplification were not associated with the OS and PFS of IDH1/2-wild-type GBM patients.